key: cord-0298203-5kufaoju authors: Chable-Bessia, Christine; Boullé, Charlotte; Neyret, Aymeric; Swain, Jitandrya; Hénaut, Mathilde; Merida, Peggy; Gros, Nathalie; Makinson, Alain; Lyonnais, Sébastien; Chesnais, Cédric B.; Muriaux, Delphine title: Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19 date: 2021-11-02 journal: bioRxiv DOI: 10.1101/2021.11.01.466865 sha: e9df8f00c323806decc05c4bfd527cfcea52d8a7 doc_id: 298203 cord_uid: 5kufaoju There are very limited antiviral therapeutic options for coronavirus infections, therefore global drug re-purposing efforts are paramount to identify available compounds that could provide clinical benefits to patients with COVID-19. Ivermectin was first approved for human use as an endectocide in the 1980s. It remains one of the most important global health medicines in history and has recently been shown to exert in vitro activity against SARS-CoV-2. However, the macrocyclic lactone family of compounds has not previously been evaluated for activity against SARS-CoV-2. The present study aims at comparing their anti-viral activity in relevant pulmonary cell lines in vitro. Here, in vitro antiviral activity of the avermectins (ivermectin and selamectin) and milbemycins (moxidectin and milbemycin oxime) were assessed against a clinical isolate from a CHU Montpellier patient infected with SARS-CoV-2 in 2020. Ivermectin demonstrated anti-SARS-CoV-2 activity in vitro in human pulmonary cells in comparison to VeroE6 (with EC50 of 1-3 μM). Similarly, the other macrocyclic lactones moxidectin, milbemycin oxime and selamectin reduced SARS-CoV-2 replication in vitro (with EC50 of 2-5 μM). Immunofluorescence assays with ivermectin and moxidectin showed a reduction in the number of infected and polynuclear cells suggesting a drug action on viral cell fusion. However, cellular toxicity of the avermectins and milbemycins during infection showed a very low selectivity index <10 for all compounds. In conclusion, none of these agents appears suitable for human use for its anti-SARS-CoV-2 activity per se, due to low selectivity index. This is discussed in regards to recent clinical COVID studies on ivermectin. In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2 Wuhan, China [1, 2] . SARS-CoV-2 is a beta-coronavirus, which are enveloped viruses containing 3 single-strand, positive-sense RNA. No effective treatment or treatment regimen has been 4 established for coronavirus disease-2019 (COVID-19) to date and although success has been 5 achieved with vaccination modalities, there remains a need for therapeutic approaches for the 6 unvaccinated and for vaccine escape mutants. Screening existing, regulatory approved medicines 7 for potential activity against SARS-CoV-2 offers the potential to reduce unnecessary animal and 8 clinical evaluations. Repurposing requires comprehensive understanding of the 9 pharmacokinetic/pharmacodynamic relationship of the product and changes from the approved 10 posology result in potentially significant data generation requirements. Several candidates have 11 emerged from this strategy although a convincing antiviral therapy has yet to emerge. The directly 12 antiviral remdesivir has conflicting efficacy data, and lopinavir/ritonavir, hydroxychloroquine and 13 ivermectin have been successively ruled out in randomized clinical trials [3] [4] [5] [6] . Dexamethasone 14 for oxygen-requiring patients has evidence of clinically-relevant efficacy in the RECOVERY trial 15 [7] , through reduction of the inflammatory response in the latter phase of the infection. Therefore, 16 the therapeutic arsenal is still limited and further options are needed. 17 Ivermectin (IVM) is a widely used antiparasitic drug targeting the gamma aminobutyric acid and 18 glutamate-gated chlorine channel in invertebrates, causing flaccid paralysis of parasite and 19 becoming one of the world's most important global heath medicines, a discovery awarded a Nobel 20 prize in 2015. Apart from its antiparasitic effect against filariae and ectoparasites, there is evidence 21 of anti-inflammatory and antiviral properties on RNA-viruses, mostly of the flaviviridae family 22 (including dengue (DNV), zika, yellow fever) [8] . A study by Caly et al [9] reported that IVM 23 inhibited SARS-CoV-2 in vitro using the Vero-hSLAM assay. However, the concentration 24 resulting in 50% inhibition (IC50, 2 to 2.5 μM i.e. 1750 to 2,190 ng/mL) was several times higher 1 than the maximal plasma concentration (Cmax) that can be reached after the oral administration of 2 the FDA approved dose for onchocerciasis (200 μg/kg e.g. 14 mg for 70 kg) [10] [11] [12] Human lung 3 exposure is thought to reach a maximum of 772 ng/mL [13] . IVM doses up to 120 mg have been 4 administered and appeared well tolerated, but with limited experience; the in vitro IC50 by Caly et 5 al was > 9-fold and > 21-fold higher than the day 3 plasma and lung tissue simulated Cmax 6 respectively, following a higher dose IV regimen of 600 μg/kg dose daily for 3 days. This dose 7 scenario exceeds the highest regulatory approved dose of IVM of 200 μg/kg single dose for the 8 treatment of strongyloidiasis. 9 IVM is generally well tolerated [14], except for potential neurotoxicity that could be linked to 10 GABA-gated channel in the central nervous system of mammals if the blood-brain barrier (BBB) 11 integrity is damaged, a possible mechanism of COVID-19 encephalopathy during the cytokinic 12 storm. This neurotoxicity in enhanced in case of mutations of the P-glycoprotein (P-gp), one of the 13 main BBB efflux-pump, for which IVM is a substrate. 14 Put together, these results highlight the importance of pharmacokinetic considerations, 15 acknowledging that discrepancies between in vitro and in vivo results have been observed. For 16 instance, DNV's (dengue virus) IC50 is even higher (17 μM) [15]. 17 SARS-CoV-2 enters host cells by binding to angiotensin-converting enzyme 2 (ACE2) receptors, 18 widely distributed in human tissue but predominantly in human alveolar epithelial cells [16, 17] 19 Mechanisms underlying the possible antiviral effect of IVM include its ability to bind to the host's 20 importin (IMP) ⍺ leading to dissociation of the IMP ⍺/β1 heterodimer and modifying the 21 interaction of IMP with viral proteins therefore hampering nuclear import [18, 19] . Other hypothesis 22 include allosteric modulation of the ⍺7 nicotinic acetylcholine receptor (nAChR) [20, 21] . 23 IVM belongs to the wider family of macrocyclic lactones, being synthesized through a semi-1 fermentation pathway through bacteria of the Streptomyces genus. The macrocyclic lactones are 2 divided into two classes: avermectins (ivermectin, doramectin, selamectin) and milbemycins 3 (moxidectin and milbemycin oxime) depending on the substitution at the position 13 of the 4 macrolide ring, also common to macrolide antibiotics (also investigated as potential antiviral 5 molecules in SARS-CoV-2 infection). IVM and moxidectin (MOX, achieved FDA-approval for 6 onchocerciasis [22] [23] [24] ) are the only macrocyclic lactones approved for human use by a regulatory 7 authority, while selamectin, doramectin and milbemycin oxyme are approved for veterinary use 8 only. Similarities across these drugs include mode of action and lipophilic properties leading to 9 preferential deposition in adipose tissues, but they differ in the degree they are substrates for 10 transporters, GABA and glutamate gated chloride channel binding, and their respective absorption, 11 distribution, metabolism and excretion (ADME) profiles. Moxidectin's human elimination half 12 time (t1/2) reaching > 20 days following oral administration [25, 26] . MOX is also a weak substrate 13 of P-gp, and has demonstrated lower neurotoxicity in models of neurotoxicosis. 14 To explore the potential of this class of compounds against SARS-CoV-2, we screened avermectins 15 and milbemycins for their antiviral efficacy in vitro. 16 17 Materials and methods 18 Cell lines and culture 19 Vero E6 cells (African green monkey kidney cells) were obtained from ECACC and maintained in 20 Dulbecco's minimal essential medium (DMEM) supplemented with 10% heat inactivated fetal 21 bovine serum (FBS) 50 U/mL of penicillin, 50µg/mL of streptomycin, 25mM of HEPES at 37°C 22 with 5% CO2. The human pulmonary alveolar A549-hACE2 cells were engineered using a 23 lentiviral vector from Flash Therapeutics (Toulouse, France) to express the human receptor ACE2. 24 6 A549 cells obtained from ECACC(#86012804) were transduced and maintained in RPMI 1 supplemented with 10% heat inactivated fetal bovine serum (FBS), 50 U/mL of penicillin, 2 50 µg/mL of streptomycin, 25mM of HEPES and 1mM of sodium pyruvate at 37°C with 5% CO2. 3 Cells were then sorted by FACS in order to obtain a A549-hACE2 population stably expressing 4 hACE2. Calu-3 cells (epithelial lung adenocarcinoma cells) were obtained from Elabscience (#EP-5 CL-0054) and maintained in DMEM supplemented with 10% heat inactivated FBS, 50 U/mL of 6 penicillin, 50µg/mL of streptomycin, 25 mM of HEPES at 37°C with 5% CO2. fluorescence images were generated using a Cell-Discoverer 7 LMS900 confocal laser-scanning 1 microscope (Zeiss). DAPI-stained nuclei surfaces were analyzed using ZEN software (Otsu 2 threshold method) from a grid of 8x8 images taken at 20x magnification. The percentage of 3 polynuclei cells were quantified manually for a total of 1000-1200 cells. For intensity analysis, 4 cells were imaged as Z stack with 0.3 µm sections then Z projection images were processed for 5 total intensity per cell using ImageJ/Fiji. Statistical tests were performed using Origin 8.5 software. 6 Statistical significance was evaluated using one-way ANOVA tests. **p < 0.05. 7 8 In vitro antiviral activity of avermectins or milbemycins in simian VeroE6 cells 10 To determine if avermectins or milbemycins could protect cells from SARS-CoV-2 infection and 11 to evaluate their toxicity, a cytopathic effect (CPE) reduction assay was first performed on African 12 green monkey kidney-derived cell line Vero E6, which present an ACE2 receptor and are widely 13 used as infection models for SARS-CoV-2 and for antiviral screening. We compared two 14 commercial assays for determining cell viability, both based on quantitation of cellular metabolism; 15 i.e. an MTS assay and ToxGlo assay ( Figure S1 ). Vero E6 cells were pretreated with serial dilutions 16 of the drugs, then infected with SARS-CoV-2, and were kept in the medium with compounds for 17 72 hours. Table 1 and Figure 1B recapitulate the main features of the evaluated compounds, 18 including the dose-response curves for both assays and estimation of the 50% cytotoxic 19 concentration (CC50). The EC50 A549-hACE2 for MOX, IVM and MIL were comparable both by MTS and by RT-qPCR and 5 matched the EC50 measured in VeroE6 cells, in the range of 2 µM. Cellular toxicity was similar for 6 the three tested compounds, close to ̴ 6 µM. MOX appeared as the best compound with an 7 EC50 MOX = 1.3 and a SI slightly increased, from 1.6 in Vero E6 cells to 4.7 in A549hACE2 cells. 8 In addition, the increase in cell proliferation was not seen in the A549-hACE2 cells. Together, these 9 results suggest that IVM, MOX and MIL provide inhibitory effects against SARS-CoV-2 infection 10 in human pulmonary cells, albeit associated with a poor selectivity. The results are reported in Figure 3 and . 15 We included IVM and remdesivir as control for our screening procedure to compare our result to 16 previously published data. For IVM, we found similar EC50 (2. 16 Cotreau et al. conducted the first safety study of MOX in humans, as an ascending-dose study. In 17 cohorts with higher doses, a slight increase in central neurological system grade 1-2 adverse events 18 (nausea, vomiting, and somnolence) was noticed therefore the enrollment was closed before the 19 planed 5 mg cohort, given that pharmacokinetics deemed the lowest posology for human use. showed a good tolerance profile on the largest cohort so far (n=978 patients in the MOX group), 4 as it had been shown in previous healthy volunteer studies [44] [45] [46] [47] [48] . 5 Altogether, these data suggest that even optimistic hypothesis (posology of 36 mg, lung to plasma 6 ratio 2:1, high-fat feeding x1.3) would still lead to expected lung Cmax < 750 ng/mg after 7 administration of 5x the currently approved dose, for a predicted lung Cmax/EC50 ratio < 0.2. 9 Very limited data on pharmacokinetics of other macrocyclic lactones (MIL, DOR and SEL) exist, 10 mostly coming from isolated studies in animals. SEL is exclusively used as a topical formulation of 6 mg/kg in cats and dogs, generally well (Figure 4 ). In addition, SARS-CoV-2 infected MOX/IVM treated cells 19 present a reduction of S-dependent syncytia in vitro (Figure 4) , suggesting a prevention of syncytia 20 formation, by an unknown mechanism that could only be due to the reduction of viral replication. 21 These results, although indirectly, are also compatible with a mechanism implying the ability of 22 those drugs to bind to the importin (IMP) ⍺ hampering nuclear import [18, 19] , thus impairing viral 23 replication in general or by interfering with the SpikeRBD-hACE2 complex formation, as 1 suggested by Lehrer S, Rheinstein PH (2020). 2 3 Our study is the first to examine antiviral parameters of macrocyclic lactones other than IVM on 4 SARS-CoV-2, nevertheless the data we provide here are only in vitro data, and the recent 5 developments encourage us to emphasize that they should therefore be taken cautiously, and that 6 many steps are to be completed before any result can be translated into clinical practice. Clinical 7 risk-benefit balance is not in favor of the use of any of these molecules at this early stage. In order 8 to try to approach the pharmacokinetic parameters of the molecules concerned, we used the data 9 available for avermectins and milbemycins, often obtained from animal data; which do not directly 10 allow an extrapolation to humans. Nevertheless, the concordance of all the data suggesting the 11 impossibility of reaching even an imperfect pharmacological target of Cmax:EC50 and therefore 12 even less able to reach Cmin:EC90 seemed important to us to avoid inappropriate conclusions being 13 reached drawn from these data. 14 Next steps and conclusion 15 Altogether our results clearly show that none of these agents is suitable for human use for its anti-16 SARS-CoV-2 activity per se. Our data show that DOR, MIL, and SEL are not clinically relevant 17 candidates. They are not approved for human use, and therefore should not be used, and there is no 18 rationale in our data to conduct the extensive studies that this would require (toxicology, impurity 19 profile, thorough ADME evaluation if tolerated, to enhance local lung delivery, as the proof-of-concept study on nebulized IVM by 3 Chaccour et al. investigated [62] . However, another just released study shows that in vitro cell 4 culture of human primary airway epithelium, there is no inhibition of SARS-CoV2 replication 5 reinforcing the idea that this drug might have no effect on virus replication in vivo [63]. A new coronavirus associated with human respiratory disease 5 in China A pneumonia outbreak associated with a new 7 coronavirus of probable bat origin A Trial of Lopinavir-Ritonavir in Adults Hospitalized with 9 Severe Covid-19 Effect of Hydroxychloroquine in Hospitalized 11 Patients with Covid-19 Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial Effect of Ivermectin on Time to Resolution 16 of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial Covid-19 -Preliminary Report Ivermectin: a systematic review from antiviral effects to 21 COVID-19 complementary regimen The FDA-approved drug 1 ivermectin inhibits the replication of SARS-CoV-2 in vitro The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19 Keeping Rigor in Times of Urgency widespread interest, an FDA warning, two letters to the editor and the 8 authors' responses Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans 11 Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing Serious adverse 14 reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan 15 Ivermectin is a specific 17 inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue 18 virus Tissue 20 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in 21 understanding SARS pathogenesis Angiotensin-converting enzyme 2 1 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target The broad spectrum antiviral ivermectin targets 4 the host nuclear transport importin α/β1 heterodimer Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The 6 Real Deal? Ivermectin: a positive allosteric effector of the 8 alpha7 neuronal nicotinic acetylcholine receptor A nicotinic hypothesis for Covid-19 with 10 preventive and therapeutic implications A randomized, single-12 ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus 13 infection Research for new drugs for elimination of onchocerciasis in Africa Single dose moxidectin versus ivermectin for 17 Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a 18 randomised, controlled, double-blind phase 3 trial Comparison of the pharmacokinetics of moxidectin 20 (Equest) and ivermectin (Eqvalan) in horses Comparison of 1 the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs Detection of 2019 novel coronavirus (2019-nCoV) 4 by real-time RT-PCR Remdesivir and chloroquine effectively inhibit the 6 recently emerged novel coronavirus (2019-nCoV) in vitro Remdesivir, lopinavir, emetine, and 8 homoharringtonine inhibit SARS-CoV-2 replication in vitro Ivermectin confers its cytotoxic effects by inducing 11 AMPK/mTOR-mediated autophagy and DNA damage Ivermectin induces cell cycle arrest and apoptosis of 13 HeLa cells via mitochondrial pathway Cell entry mechanisms of SARS-CoV-2 SARS-CoV-2 tropism, entry, replication, and 17 propagation: Considerations for drug discovery and development Chloroquine does not inhibit 20 infection of human lung cells with SARS-CoV-2 Syncytia formation by SARS-CoV-2-infected 1 cells Minimal system for assembly of SARS-CoV-2 virus 3 like particles Construction of SARS-CoV-2 Virus-Like Particles by 5 SARS-CoV-2 viral budding and entry can be 7 modeled using BSL-2 level virus-like particles The SARS-CoV-2 envelope and membrane proteins 9 modulate maturation and retention of the spike protein Cultured human airway epithelial cells (calu-3): a model 12 of human respiratory function, structure, and inflammatory responses Prioritization of Anti-SARS-Cov-2 Drug Repurposing 15 Opportunities Based on Plasma and Target Site Concentrations Derived from their Established 16 The pharmacokinetics of 18 moxidectin after oral and subcutaneous administration to sheep Moxidectin in cattle: correlation between plasma and 20 target tissues disposition The effect of a high-fat breakfast on the 1 pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial The antiparasitic moxidectin: safety, tolerability, 4 and pharmacokinetics in humans Excretion of moxidectin into breast milk and 6 pharmacokinetics in healthy lactating women Relative 9 Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin Effect of moxidectin on CYP3A4 activity as 12 evaluated by oral midazolam pharmacokinetics in healthy subjects Macrocyclic lactones in antiparasitic therapy Pharmacokinetics of selamectin following intravenous, oral and topical administration in cats and 18 dogs Comparative pharmacokinetics of 20 doramectin and ivermectin in cattle Oral Administration in Horses* Pharmacokinetics of 3 spinosad and milbemycin oxime administered in combination and separately per os to dogs Serious reactions after mass treatment of onchocerciasis with ivermectin in an 9 area endemic for Loa loa infection Serious Ivermectin Toxicity and Human ABCB1 11 Nonsense Mutations Selamectin: a novel broad-spectrum endectocide 13 for dogs and cats Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological 16 Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats Moxidectin and the avermectins: Consanguinity but not 21 26 identity Covid-19 -Interim WHO Solidarity Trial Results Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats Maarten van den Berge, Martijn C. Nawijn, Ymkje Stienstra, Izabela A Rodenhuis Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 10 cells but not in human primary airway epithelium cells The authors have no competing interests. deduced from viral CPE after remdesivir cell treatment (red line). 10